{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:33:30Z","timestamp":1789842810523,"version":"4.0.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"DOI":"10.7759\/cureus.76751","type":"journal-article","created":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T22:56:49Z","timestamp":1735772209000},"source":"Crossref","is-referenced-by-count":3,"title":["Treatment of Methotrexate-Associated Lymphoproliferative Disorder With Biological Therapies"],"prefix":"10.7759","author":[{"given":"Kava C","family":"Afu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S","family":"Durkee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Complications of immunosuppression associated with weekly low dose methotrexate","volume":"18","author":"Shiroky JB","year":"1991","unstructured":"Shiroky JB, Frost A, Skelton JD, Haegert DG, Newkirk MM, Neville C. Complications of immunosuppression associated with weekly low dose methotrexate. J Rheumatol. 1991, 18:1172-5.","journal-title":"J Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.19007","article-title":"Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders","volume":"59","author":"Tokuhira M","year":"2019","unstructured":"Tokuhira M, Tamaru JI, Kizaki M. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. J Clin Exp Hematop. 2019, 59:72-92. 10.3960\/jslrt.19007","journal-title":"J Clin Exp Hematop"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.11.3909","article-title":"Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France","volume":"99","author":"Mariette X","year":"2002","unstructured":"Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002, 99:3909-15. 10.1182\/blood.v99.11.3909","journal-title":"Blood"},{"key":"ref4","article-title":"Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication","volume":"34","author":"Hoshida Y","year":"2007","unstructured":"Hoshida Y, Xu JX, Fujita S, et al.. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007, 34:322-31.","journal-title":"J Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001271","article-title":"Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors","volume":"43","author":"Kurita D","year":"2019","unstructured":"Kurita D, Miyoshi H, Ichikawa A, et al.. Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors. Am J Surg Pathol. 2019, 43:869-84. 10.1097\/PAS.0000000000001271","journal-title":"Am J Surg Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5414\/CP203604","article-title":"Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"58","author":"Inose R","year":"2020","unstructured":"Inose R, Hashimoto N, Hosomi K, Yokoyama S, Takada M. Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2020, 58:131-8. 10.5414\/CP203604","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2004.01676.x","article-title":"Malignancies in organ transplant recipients","volume":"54","author":"Hoshida Y","year":"2004","unstructured":"Hoshida Y, Aozasa K. Malignancies in organ transplant recipients. Pathol Int. 2004, 54:649-58. 10.1111\/j.1440-1827.2004.01676.x","journal-title":"Pathol Int"},{"key":"ref8","article-title":"The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression","volume":"133","author":"Nalesnik MA","year":"1988","unstructured":"Nalesnik MA, Jaffe R, Starzl TE, et al.. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol. 1988, 133:173-92.","journal-title":"Am J Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh313","article-title":"Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas","volume":"96","author":"Feng WH","year":"2004","unstructured":"Feng WH, Cohen JI, Fischer S, et al.. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004, 96:1691-702. 10.1093\/jnci\/djh313","journal-title":"J Natl Cancer Inst"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.2.339","article-title":"Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells","volume":"177","author":"Deacon EM","year":"1993","unstructured":"Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med. 1993, 177:339-49. 10.1084\/jem.177.2.339","journal-title":"J Exp Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199305063281806","article-title":"Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis","volume":"328","author":"Kamel OW","year":"1993","unstructured":"Kamel OW, van de Rijn M, Weiss LM, et al.. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993, 328:1317-21. 10.1056\/NEJM199305063281806","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21003","article-title":"Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection","volume":"82","author":"Miyazaki T","year":"2007","unstructured":"Miyazaki T, Fujimaki K, Shirasugi Y, et al.. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol. 2007, 82:1106-9. 10.1002\/ajh.21003","journal-title":"Am J Hematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199610000-00015","article-title":"Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy","volume":"20","author":"Kamel OW","year":"1996","unstructured":"Kamel OW, Weiss LM, van de Rijn M, Colby TV, Kingma DW, Jaffe ES. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol. 1996, 20:1279-87. 10.1097\/00000478-199610000-00015","journal-title":"Am J Surg Pathol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/2040620711412417","article-title":"Therapeutic options in post-transplant lymphoproliferative disorders","volume":"2","author":"Zimmermann H","year":"2011","unstructured":"Zimmermann H, Trappe RU. Therapeutic options in post-transplant lymphoproliferative disorders. Ther Adv Hematol. 2011, 2:393-407. 10.1177\/2040620711412417","journal-title":"Ther Adv Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.878953","article-title":"Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab","volume":"14","author":"Tischer-Zimmermann S","year":"2023","unstructured":"Tischer-Zimmermann S, Bonifacius A, Santamorena MM, et al.. Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab. Front Immunol. 2023, 14:878953. 10.3389\/fimmu.2023.878953","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02127-9","article-title":"Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy","volume":"59","author":"Soci\u00e9 G","year":"2024","unstructured":"Soci\u00e9 G, Barba P, Barlev A, et al.. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy. Bone Marrow Transplant. 2024, 59:52-8. 10.1038\/s41409-023-02127-9","journal-title":"Bone Marrow Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5045\/br.2017.52.4.243","article-title":"Brentuximab vedotin: clinical updates and practical guidance","volume":"52","author":"Yi JH","year":"2017","unstructured":"Yi JH, Kim SJ, Kim WS. Brentuximab vedotin: clinical updates and practical guidance. Blood Res. 2017, 52:243-53. 10.5045\/br.2017.52.4.243","journal-title":"Blood Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/251929-treatment-of-methotrexate-associated-lymphoproliferative-disorder-with-biological-therapies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T22:56:51Z","timestamp":1735772211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/251929-treatment-of-methotrexate-associated-lymphoproliferative-disorder-with-biological-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.76751","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}